52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Biomarin And Skyline Therapeutics Announce Strategic Collaboration
Biomarin Receives FDA Approval For Voxzogo For Injection
FDA Approves First Drug To Improve Growth In Children With Most Common Form Of Dwarfism
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s portfolio consists of commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The Company's commercial products include Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochloride), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alpha) and Voxzogo (vosoritide). The Company's pipeline includes Valoctocogene Roxaparvovec for Severe Hemophilia A, Vosoritide for Achondroplasia, BMN 307 for Phenylketonuria (PKU) and BMN 331 for Hereditary Angioedema (HAE).
Biotechnology & Drugs
105 Digital Dr
Chairman of the Board, Chief Executive Officer
Brian R. Mueller
Chief Financial Officer, Executive Vice President
Henry J. Fuchs
President - Worldwide Research & Development
C. Greg Guyer
Chief Technical Officer, Executive Vice President of Global Manufacturing, Technical Operations
G. Eric Davis
Executive Vice President, General Counsel, Secretary
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
BioMarin Pharmaceutical Inc's once-daily injection for children with the most common type of dwarfism received clearance from the U.S. health regulator on Friday, making it the first approved therapy for achondroplasia in the country.
U.S.-based Biomarin Pharmaceutical Inc's treatment for one of the most common forms of dwarfism received clearance from the European Commission, becoming the first therapy to get an approval in the region for achondroplasia.
The U.S. Food and Drug Administration rejected BioMarin Pharmaceutical Inc's gene therapy for bleeding disorder hemophilia A citing the need for longer-term data, the drugmaker said on Wednesday, potentially pushing any approval out to 2022.
The U.S. Food and Drug Administration has declined to approve BioMarin Pharmaceutical Inc's gene therapy for bleeding disorder hemophilia A, citing the need for two-year data on the therapy, the drugmaker said on Wednesday.
* BIOMARIN PROMOTES COMPANY VETERAN, BRIAN R. MUELLER, TO EXECUTIVE VICE PRESIDENT, CFO Source text for Eikon: Further company coverage:
* BIOMARIN PROVIDES ADDITIONAL DATA FROM RECENT 4 YEAR UPDATE OF ONGOING PHASE 1/2 STUDY OF VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY FOR SEVERE HEMOPHILIA A IN LATE-BREAKING ORAL PRESENTATION AT WORLD FEDERATION OF HEMOPHILIA VIRTUAL SUMMIT Source text for Eikon: Further...
* BIOMARIN ANNOUNCES PRICING OF UPSIZED $550 MILLION SENIOR SUBORDINATED CONVERTIBLE NOTES OFFERING
* BIOMARIN ANNOUNCES PROPOSED PRIVATE OFFERING OF $500 MILLION OF SENIOR SUBORDINATED CONVERTIBLE NOTES
* BIOMARIN EXTENDS GENE THERAPY LEADERSHIP WITH DINAQOR IN A PRECLINICAL COLLABORATION AND LICENSE AGREEMENT TO DEVELOP GENE THERAPIES FOR RARE GENETIC CARDIOMYOPATHIES
* BIOMARIN ANNOUNCES FIRST QUARTER 2020 TOTAL REVENUE GROWTH OF 25% TO $502 MILLION
* BIOMARIN PLANS REGULATORY SUBMISSIONS FOR MARKETING AUTHORIZATION OF VOSORITIDE TO TREAT CHILDREN WITH ACHONDROPLASIA IN 3Q 2020 IN BOTH US AND EUROPE Source text for Eikon: Further company coverage:
* BIOMARIN ANNOUNCES FOURTH QUARTER AND RECORD FULL-YEAR 2019 FINANCIAL RESULTS
Sanofi SA's Genzyme unit cannot block a former employee from joining BioMarin Pharmaceutical Inc, where he would help launch a gene therapy treatment for hemophilia that would compete with a drug his ex-employer markets, a Massachusetts judge has ruled.
* Q3 REVENUE $461.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $454.5 MILLION
BioMarin Pharmaceutical Inc said on Tuesday early trial data for its gene therapy for hemophilia A suggested the one-time infusion's effect on some patients' bleeding disorders would last eight years.
* BIOMARIN CEO SAYS BELIEVES ONCE HEMOPHILIA GENE THERAPY IS APPROVED CO WILL BE IN 'PRETTY GOOD SHAPE' FOR DISCUSSION ON PRICE WITH PAYERS BASED ON FIVE YEARS OF COSTS, SIMILAR TO NOVARTIS
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.